Peregrine Pharmaceuticals (NASDAQ:PPHM) announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies investigating the therapeutic potential of Peregrine’s phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with approved and developmental cancer immunotherapies and translation data in patients with lung cancer. Peregrine’s lead PS-targeting antibody, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the “SUNRISE trial”) along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.

Abstract details:

Abstract Number: 274

Presentation Title: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer 
Presentation Time: Sunday, April 19, 2015, 1:00 PM – 5:00 PM Eastern Daylight Time 
Location: Section 13 
Poster Board Number: 2 
Author Block: Soner Altiok1, Melanie Mediavilla-Valera2, Jenny Kreahling2, David Noyes2, Tiffany N. Razabdouski2, Nikoletta L. Kallinteris3, Joseph Shan3, Scott Antonia2. 1Nilogen Oncosystems, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL; 3Peregrine Pharmaceuticals, Inc, Tustin, CA

Abstract Number: 252

Presentation Title: Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models 
Presentation Time: Sunday, April 19, 2015, 1:00 PM – 5:00 PM Eastern Daylight Time 
Location: Section 12 
Poster Board Number: 10 
Author Block: Bruce Freimark1, Jian Gong1, Dan Ye2, Rolf Brekken2, Shen Yin1, Jeff Hutchins1, Van Nguyen1, Chris Hughes3, Xianming Huang2. 1Peregrine Pharmaceuticals, Inc, Tustin, CA; 2UT Southwestern Medical Center, Dallas, TX; 3University of California, Irvine,Irvine, CA

Abstract Number: 4289

Presentation Title: Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors 
Presentation Time: Tuesday, April 21, 2015, 1:00 PM – 5:00 PM Eastern Daylight Time 
Location: Section 24 
Poster Board Number: 19 
Author Block: Jian Gong, Shen Yin, Van Nguyen, Jeff Hutchins, Bruce D. Freimark. Peregrine Pharmaceuticals, Inc., Tustin, CA (Original Source)

Shares of Peregrine closed yesterday at $1.43 . PPHM has a 1-year high of $2 and a 1-year low of $1.19. The stock’s 50-day moving average is $1.41 and it’s 200-day moving average is $1.41.

On the ratings front, Peregrine has been the subject of a number of recent research reports. In a report issued on March 13, MLV & Co. analyst Thomas Yip reiterated a Buy rating on PPHM, with a price target of $3.50, which represents a potential upside of 144.8% from where the stock is currently trading. Separately, on January 16, Roth Capital’s Joseph Pantginis reiterated a Buy rating on the stock and has a price target of $5.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Thomas Yip and Joseph Pantginis have a total average return of 3.1% and 14.5% respectively. Yip has a success rate of 33.3% and is ranked #2283 out of 3574 analysts, while Pantginis has a success rate of 55.9% and is ranked #73.

Peregrine Pharmaceuticals Inc is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for treatment & diagnosis of cancer. With its phosphatidylserine-targeting platform, it is pursuing two clinical programs in cancer.